 "Kyodo News International (Tokyo, Japan)")
|
Mitsubishi Pharma, Tanabe weigh merger around October.
|
Jan. 19--OSAKA -- Mitsubishi Pharma Corp., a wholly owned subsidiary of Mitsubishi Chemical Holdings Corp., is discussing merging with another drugmaker, Tanabe Seiyaku Co., around October, the companies said Thursday.
The deal being contemplated is expected to catapult the merged firm into sixth place in Japan's pharmaceutical industry amid intensifying competition at home and abroad, industry observers say.
Asked about merging in October, a Mitsubishi Pharma source said, "If we try to do it soon, I think it's possible." Mitsubishi Pharma ranks ninth in the business in ...
|
CRUCELL/DSM SIGN LICENSING PACT WITH MITSUBISHI PHARMA.
Newspaper article from: Worldwide Biotech
; ...the Japanese pharmaceutical company Mitsubishi Pharma Corporation. This license agreement...Ltd. in Japan. About Mitsubishi Mitsubishi Pharma Corporation is a global research...Pharmaceuticals, Inc., on October 1, 2001. Mitsubishi Pharma Corporation has established a strong...
|
|
Mitsubishi Pharma entered into a one-year site license agreement for Safe-Hit.(Microarrays: sales/orders of note)(Brief Article)
Newspaper article from: Instrument Business Outlook
; Mitsubishi Pharma entered into a one-year site license agreement for Safe-Hit, a microarray-based system developed by drug discovery company ExonHit Therapeutics for evaluation and ranking of compounds for toxicity.
|
|
|
DYNOGEN ACQUIRES EXCLUSIVE RIGHTS TO PUMOSETRAG.
Newspaper article from: Worldwide Biotech
; ...clinical-stage compound pumosetrag from Mitsubishi Pharma Corporation. Pumosetrag was previously...visit http://www.dynogen.com. About Mitsubishi Pharma Corporation Mitsubishi Pharma Corporation, a research-driven pharmaceutical...
|
|
Dynogen awarded broad United States patent relating to treatment of lower urinary tract disorders.
Newspaper article from: BIOTECH Patent News
; ...patent strategy, he added. DDP225 was previously studied by Mitsubishi Pharma Corporation in Phase II clinical trials for depression...DDP225 and all related preclinical and clinical data from Mitsubishi Pharma in October 2003. Access to Phase II safety and pharmacokinetic...
|
|
|
VERTEX/MITSUBISHI TO DEVELOP HCV ORAL PROTEASE INHIBITOR.
Newspaper article from: Worldwide Biotech
; ...Pharmaceuticals Incorporated (Nasdaq: VRTX), Cambridge, Mass., and Mitsubishi Pharma Corporation have signed an agreement to develop and commercialize...Managing Officer, Division Manager of Strategic Planning at Mitsubishi Pharma Corporation. Through this partnership with Vertex, a leader...
|
|
|
Dynogen enters into irritable bowel syndrome agreement with Mitsubishi.(Dynogen Pharmaceuticals Inc., Mitsubishi Pharma Corp.)
Newspaper article from: BIOTECH Patent News
; ...pipeline, Dynogen Pharmaceuticals, Inc. (Boston, MA) has entered into a Technology Transfer and License agreement with Mitsubishi Pharma Corporation involving a neurological compound that Dynogen will develop for the treatment of irritable bowel syndrome...
|
|
Cycloheximide shortage feared imminent.(Brief Article)
Magazine article from: Modern Brewery Age
; ...reports that industry stocks of cycloheximide, a Fungicide antiobiotic used for checking yeast quality, are dwindling fast. Tanabe Seiyaku, the chemical company in Osaka, Japan that holds the sole rights to manufacture the substance, does not make it anymore...
|
|
NEC Verifies Effectiveness of New Drug Screening System Utilizing Active Learning.
Magazine article from: JCN Newswires
; ...compared with conventional screening systems. The system's effectiveness has been verified through collaborative research with Tanabe Seiyaku Co., Ltd, a Japanese pharmaceutical company, to which the system will be delivered in September. The main points of this...
|
|
Local firm raises $107.7 million in net proceeds on Japanese exchange.(Biotech)(MediciNova Inc.)
Magazine article from: San Diego Business Journal
; ...set up the firm four years ago. Kiyoizumi is a former chief executive of Tanabe Research Laboratories, the U.S. arm of Tanabe Seiyaku Co., Japan's oldest and 10th largest pharmaceutical company. Secondly, 70 percent of the firm's venture capital backers...
|
|
|
Japan.(Region Watch)
Newspaper article from: Instrument Business Outlook
; ...R&D spending of $2.0 billion), Daiichi Sankyo ($1.5 billion), Eisai ($1.3 billion), Astellas Pharma ($1.2 billion) and Mitsubishi Pharma ($671 million). Among the top 20 companies, 2007 R&D spending topped 20% of sales Takeda, Kyowa Hakko Kirin Pharma and...
|
Find more facts and information related to the
article "Mitsubishi Pharma, Tanabe weigh merger around ..."
